In vivo inhibition of human CYP1A2 activity by oltipraz

Cancer Chemotherapy and Pharmacology

Volumn 47, Issue 6, 2001, Pages 505-510

  Sofowora, Gbemiga G ^a   Choo, Edna F ^a   Mayo, Gail ^a   Shyr, Yu ^a   Wilkinson, Grant R ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Caffeine metabolism; CYP1A2; Drug interaction; Oltipraz

Indexed keywords

CAFFEINE; CARCINOGEN; CYTOCHROME P450 1A2; OLTIPRAZ; PARAXANTHINE; XENOBIOTIC AGENT;

ADULT; ARTICLE; CANCER PREVENTION; DEMETHYLATION; DRUG HALF LIFE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS; CAFFEINE; CYTOCHROME P-450 CYP1A2; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; METHYLATION; PYRAZINES; THEOPHYLLINE;

EID: 0035011152     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000245     Document Type: Article

References (29)

1. 1. Benson AB III (1993) Oltipraz: a laboratory and clinical review. J Cell Biochem Suppl 17F:278
2. 1 biotransformation in rat liver: implications for human chemointervention. Cancer Res 56:2306
3. 3. Buetler TM, Gallagher EP, Wang C, Stahl DL, Hayes JD, Eaton DL (1995) Induction of phase I and phase II drug-metabolizing enzyme mRNA, protein, and activity by BHA, ethoxyquin, and oltipraz. Tox Appl Pharmacol 135:45
4. 4. Casoli P, Verine H (1990) High performance liquid chromatographic determination of methylxanthines in canine serum, gastric and pancreatic juices. Biomed Chromatogr 4:209
5. 5. Clapper ML (1998) Chemopreventive activity of oltipraz. Pharmacol Ther 78:17
6. 6. Fuhr U, Rost KL, Engelhardt R, Sachs M, Liermann D, Belloc C, Beaune P, Janezic S, Grant D, Meyer UA, Staib AH (1996) Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics 6:159
7. 1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P4501A2 and 3A4. Toxicol Appl Pharmacol 141:595
8. 8. Guengerich FP (1995) Human cytochrome P450 enzymes. In: Ortiz de Montellano PR (ed) Cytochrome P450: structure, mechanism, and biochemistry. Plenum, New York, p 473
9. 9. Gupta E, Olopade OI, Ratain MJ, Mick R, Baker TM, Berezin FK, Benson AB III, Dolan ME (1995) Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent. Clin Cancer Res 1:1133
10. 10. Jacobson LP, Zhang B-C, Zhu Y-R, Wang J-B, Wu Y, Zhang Q-N, Yu L-Y, Qian G-S, Kuang S-Y, Li Y-F, Fang X, Zarba A, Chen B, Enger C, Davidson NE, Gorman MB, Gordon GB, Prochaska HJ, Egner PA, Groopman JD, Muñoz A, Helzlsouer KJ, Kensler TW (1997) Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes. Cancer Epidemiol Biomarkers Prev 6:257
11. 11. Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet RA, Sigman CC (1994) Chemopreventive drug development: perspectives and progress. Cancer Epidemiol Biomarkers Prev 3:85
12. 12. Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet RA, Doody LA, Malone WF, Hawk ET, Sigman CC (1996) New agents for cancer chemoprevention. J Cell Biochem 26S:1
13. 13. Kensler TW, Egner PA, Dolan PM, Groopman JD, Roebuck BD (1987) Mechanism of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) and related 1,2-dithiol-3-thiones and 1,2-dithiol-3-ones. Cancer Res 47:4271
14. 14. Kensler TW, Groopman JD, Sutter TR, Curphey TJ, Roebuck BD (1999) Development of cancer chemopreventive agents: oltipraz as a paradigm. Chem Res Toxicol 12:113
15. 15. Kensler TW, Helzlsouer KJ (1995) Oltipraz: clinical opportunities for cancer chemoprevention. J Cell Biochem Suppl 22:101
16. 1 metabolism in human hepatocytes in primary culture. Cancer Res 55:5574
17. 17. Langouët S, Furge LL, Kerriguy N, Nakamura K, Guillouzo A, Guengerich FP (2000) Inhibition of human cytochrome P450 enzymes by 1,2-dithiol-3-thione, oltipraz and its derivatives, and sulforaphane. Clin Res Toxicol 13:245
18. 18. Langouët S, Mahéo K, Berthou F, Morel F, Lagadic-Gossman D, Glaise D, Coles B, Ketterer B, Guillouzo A (1997) Effects of administration of the chemoprotective agent oltipraz on CYP1A and CYP2B in rat liver and rat hepatocytes in culture: Carcinogenesis 18:1343
19. 19. Miners JO, Birkett DJ (1996) The use of caffeine as a metabolic probe for human drug metabolizing enzymes. Gen Pharm 27:245
20. 20. O'Dwyer PJ, Szarka CE, Yao K-S, Halbherr TC, Pfeiffer GR, Green F, Gallo JM, Brennan J, Frucht H, Goosenberg EB, Hamilton TC, Litwin S, Balshem AM, Engstrom PF, Clapper ML (1996) Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolthione oltipraz. J Clin Invest 98:1210
21. 21. O'Shea D, Kim RB, Wilkinson GR (1997) Modulation of CYP2E1 activity by isoniazid in fast and slow acetylators. Br J Clin Pharmac 43:99
22. 22. Pickard CE, Stewart AD, Hartley R, Lucock MD (1986) A rapid HPLC method for monitoring plasma levels of caffeine and theophylline using solid phase extraction columns. Ann Clin Biochem 23:440
23. 1 excretion in rat urine during dietary intervention with oltipraz. Carcinogenesis 17:1385
24. 24. Tantcheva-Poór I, Zaigler M, Rietbrock S, Fuhr U (1999) Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics 9:131
25. 25. Tarrus F, Cami J, Roberts DJ, Spickett RGW, Celdran E, Segura J (1987) Accumulation of caffeine in healthy volunteers treated with furafylline. Br J Clin Pharmacol 23:9
26. 1 by oltipraz in residents of Qidong, People's Republic of China. J Natl Canc Inst 91:347
27. 27. Wattenberg LW (1993) Prevention-therapy-basic science and the resolution of the cancer problem. Cancer Res 53:5890
28. 28. Wilkinson J IV, Clapper ML (1997): Detoxication enzymes and chemoprevention. Proc Soc Exp Biol Med 216:192
29. 29. Zhang B-C, Zhu Y-R, Wang J-B, Wu Y, Zhang Q-N, Qian G-S, Kuang S-Y, Li Y-F, Fang X, Yu L-Y, DeFlora S, Jacobson LP, Zarba A, Egner PA, He X, Wang J-S, Chen B, Enger CL, Davidson NE, Gordon GB, Gorman MB, Prochaska HJ, Groopman JD, Alvaro Muñoz A, Helzlsouer KJ, Kensler TW (1997) Oltipraz chemoprevention trial in Qidong, Jiangsu Province, People's Republic of China. J Cell Biochem Suppl 28/29:166